| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/GAST.2002.34780 |
| P698 | PubMed publication ID | 12145795 |
| P50 | author | Michael Camilleri | Q64750736 |
| P2093 | author name string | Raul Urrutia | |
| Paula J Carlson | |||
| Sanna McKinzie | |||
| H Jae Kim | |||
| Elena Atanasova | |||
| Umraan Ahmad | |||
| Blanca E Viramontes | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irritable bowel syndrome | Q838966 |
| serotonin | Q167934 | ||
| diarrhea | Q40878 | ||
| P304 | page(s) | 425-432 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome | |
| P478 | volume | 123 |
| Q43339263 | 5-Hydroxytryptophan activates colonic myenteric neurons and propulsive motor function through 5-HT4 receptors in conscious mice |
| Q37069091 | A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults |
| Q39371837 | A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. |
| Q57789531 | A genetic association study of 5-HTT LPR and GN?3 C825T polymorphisms with irritable bowel syndrome |
| Q37626671 | A population-based twin study of functional somatic syndromes |
| Q34237231 | A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea |
| Q46932419 | A study of candidate genotypes associated with dyspepsia in a U.S. community |
| Q33984210 | AJG series: molecular biology for clinicians |
| Q45756295 | Abnormal gastric myoelectrical activity in postural tachycardia syndrome |
| Q92162971 | Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron |
| Q36616801 | Accommodation and peristalsis are functional responses to obstruction in rat hypertrophic ileum |
| Q34649076 | Alosetron and irritable bowel syndrome |
| Q35203790 | Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder |
| Q37434409 | Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats |
| Q37608344 | Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome |
| Q36776163 | Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome |
| Q46923413 | An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions |
| Q44884740 | Antidepressants in IBS: are we deluding ourselves? |
| Q35596886 | Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women |
| Q35694154 | Association of Serotonin Transporter Promoter Polymorphism (5HTTLPR) with Microscopic Colitis and Ulcerative Colitis: Time to Be AsSERTive? |
| Q35596567 | Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders |
| Q34333642 | Atypical antipsychotics as a possible treatment option for irritable bowel syndrome |
| Q37474400 | Autonomic testing in functional gastrointestinal disorders: implications of reproducible gastrointestinal complaints during tilt table testing |
| Q35683216 | Benefit-risk assessment of tegaserod in irritable bowel syndrome |
| Q21195658 | Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome |
| Q46709576 | Candidate genotypes associated with functional dyspepsia |
| Q36455907 | Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain |
| Q42716570 | Changing face of irritable bowel syndrome |
| Q36065990 | Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea |
| Q36613862 | Clinical application of pharmacogenetics in gastrointestinal diseases |
| Q37504791 | Colonic transit studies: normal values for adults and children with comparison of radiological and scintigraphic methods |
| Q36687444 | Contribution of gender to pathophysiology and clinical presentation of IBS: should management be different in women? |
| Q39563707 | Correlation between serum serotonin and endoscopy inflammation scores in patients with ileal pouches |
| Q37947605 | Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders |
| Q44914306 | Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod |
| Q36579818 | Drug development for the irritable bowel syndrome: current challenges and future perspectives |
| Q39397861 | Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials |
| Q36458417 | Emerging drugs for irritable bowel syndrome |
| Q37857849 | Existing and emerging therapies for irritable bowel syndrome |
| Q48447785 | Extra digestive manifestations of irritable bowel syndrome: intolerance to drugs? |
| Q35596202 | Familial aggregation of irritable bowel syndrome: a prospective study |
| Q36428527 | From the bench to the 'crib'-side: implications of scientific advances to paediatric neurogastroenterology and motility |
| Q34893529 | Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics |
| Q35753361 | Gastrointestinal pain in functional bowel disorders: sensory neurons as novel drug targets |
| Q37858651 | Gene, environment, and brain-gut interactions in irritable bowel syndrome |
| Q38119270 | Genes and functional GI disorders: from casual to causal relationship. |
| Q37216842 | Genes and irritable bowel syndrome: is there a link? |
| Q37312273 | Genetic contribution to motility disorders of the upper gastrointestinal tract. |
| Q37335246 | Genetic determination of irritable bowel syndrome |
| Q26777392 | Genetic epidemiology of irritable bowel syndrome |
| Q36079153 | Genetic factors in neuromuscular pain |
| Q27008164 | Genetic polymorphism in pathogenesis of irritable bowel syndrome |
| Q33992299 | Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics |
| Q34473834 | Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. |
| Q33989989 | Genetics of fibromyalgia |
| Q40062485 | Genetics of irritable bowel syndrome |
| Q34626602 | Guidelines on the irritable bowel syndrome: mechanisms and practical management. |
| Q30485725 | How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. |
| Q36779337 | IBS--review and what's new. |
| Q35595654 | Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome |
| Q48389586 | Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches |
| Q56965677 | Irritable bowel syndrome |
| Q36348565 | Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations? |
| Q85631567 | Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders? |
| Q44440914 | Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response |
| Q26769908 | Irritable bowel syndrome: Is it "irritable brain" or "irritable bowel"? |
| Q37205398 | Irritable bowel syndrome: a practical approach |
| Q34134491 | Irritable bowel syndrome: a review article. |
| Q26860280 | Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome |
| Q26751193 | Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment |
| Q34660338 | Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments |
| Q81090344 | Is hypnotherapy effective for pediatric functional abdominal pain or IBS? |
| Q35596897 | Is there a SERT-ain association with IBS? |
| Q35176122 | Lessons Learnt from Post-Infectious IBS. |
| Q38685668 | Lessons learned--resolving the enigma of genetic factors in IBS. |
| Q34992347 | Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome |
| Q34345704 | Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome |
| Q36667812 | Mechanisms of Disease: genetics of fibromyalgia |
| Q36724686 | Mechanisms of disease: genetics of functional gastrointestinal disorders--searching the genes that matter |
| Q36728934 | Mechanisms of hypersensitivity in IBS and functional disorders |
| Q34603143 | Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders |
| Q33433765 | New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments |
| Q36308871 | New paradigm for studying genetic contributions to irritable bowel syndrome |
| Q33432064 | New pathophysiological mechanisms in irritable bowel syndrome |
| Q57116938 | New treatments and therapeutic targets for IBS and other functional bowel disorders |
| Q35595593 | Of actors, bolting horses, and drops in oceans! |
| Q35730488 | Pathophysiologic findings of irritable bowel syndrome in china |
| Q35746810 | Pathophysiology as a basis for understanding symptom complexes and therapeutic targets |
| Q36848110 | Patterns of alternation in irritable bowel syndrome |
| Q61811468 | Personalized management in functional gastrointestinal disorders based on genomics: hope at last or just feigned praise? |
| Q38661352 | Pharmacogenetics and the treatment of functional gastrointestinal disorders |
| Q53638382 | Pharmacogenetics in irritable bowel syndrome. |
| Q37212893 | Pharmacogenetics of low dose clonidine in irritable bowel syndrome |
| Q36192802 | Pharmacogenomics and functional gastrointestinal disorders |
| Q36874393 | Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications |
| Q36019193 | Pharmacogenomics and systems biology of membrane transporters |
| Q35596862 | Pharmacology of serotonin: what a clinician should know. |
| Q34848481 | Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1 |
| Q44700991 | Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron |
| Q30924503 | Polymorphism in the oxytocin promoter region in patients with lactase non-persistence is not related to symptoms |
| Q38909322 | Polymorphisms of 5-HTT LPR and GNβ3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial |
| Q36180606 | Priorities and standards in pharmacogenetic research |
| Q24289028 | Progress in genetic studies of pain and analgesia |
| Q35730465 | Psychological Co-morbidity in Functional Gastrointestinal Disorders: Epidemiology, Mechanisms and Management |
| Q33656496 | Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story? |
| Q28072085 | Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome |
| Q38052154 | Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. |
| Q36021269 | Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders |
| Q37838476 | Review article: the pathogenesis of diverticular disease--current perspectives on motility and neurotransmitters |
| Q55527145 | Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders. |
| Q46190717 | Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice |
| Q35047066 | Role of serotonin in the pathophysiology of the irritable bowel syndrome |
| Q34675807 | S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome |
| Q44797388 | SSRIs in IBS: sensing a dash of disappointment |
| Q39396013 | Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications |
| Q35384517 | Scintigraphic biomarkers for colonic dysmotility |
| Q36728938 | Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity |
| Q46312636 | Serotonin (5-HT) release and uptake measured by real-time electrochemical techniques in the rat ileum |
| Q43274523 | Serotonin and the GI tract |
| Q37223378 | Serotonin in the gastrointestinal tract |
| Q37132811 | Serotonin pharmacology in the gastrointestinal tract: a review |
| Q35541477 | Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsia |
| Q54373755 | Serotonin transporter and G protein beta 3 subunit gene polymorphisms in Greeks with irritable bowel syndrome. |
| Q57819657 | Sex-Gender Differences in Irritable Bowel Syndrome |
| Q46771580 | Susceptibility genes and functional gastrointestinal disorders |
| Q37154305 | TPH gene polymorphisms are associated with disease perception and quality of life in women with irritable bowel syndrome |
| Q46604896 | Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care |
| Q39337639 | The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients |
| Q27024521 | The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D) |
| Q36306788 | The genetics of irritable bowel syndrome |
| Q37551099 | The role of 5-HTT LPR and GNβ3 825C>T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). |
| Q28276796 | The role of pelvic floor dysfunction and slow colonic transit in adolescents with refractory constipation |
| Q37981892 | The role of pharmacogenetics in nonmalignant gastrointestinal diseases |
| Q46079862 | Therapeutic targets |
| Q35047051 | Treating irritable bowel syndrome: overview, perspective and future therapies |
| Q36304083 | Treatments targeting putative mechanisms in irritable bowel syndrome |
| Q37205403 | Update on irritable bowel syndrome and gender differences |
| Q37156627 | Updates on treatment of irritable bowel syndrome |
| Q34983471 | What does irritable bowel syndrome share with non-alcoholic fatty liver disease? |
Search more.